<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362134">
  <stage>Registered</stage>
  <submitdate>21/02/2012</submitdate>
  <approvaldate>13/11/2012</approvaldate>
  <actrnumber>ACTRN12612001194853</actrnumber>
  <trial_identification>
    <studytitle>The Efavirenz (EFV) central nervous system exposure sub-study</studytitle>
    <scientifictitle>The CNS sub-study of a randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus 2N(t)RTI in antiretroviral-naive HIV-infected individuals over 96 weeks</scientifictitle>
    <utrn />
    <trialacronym>The CNS sub-study for Encore1</trialacronym>
    <secondaryid>NCT01451333 ClinicalTrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tenofovir (TDF) (300mg qd (once daily))/emtricitabine (FTC) (200mg qd) + efavirenz(EFV )(600mg qd; 3 x 200mg qd) all oral tablets</interventions>
    <comparator>Tenofovir (TDF) (300mg qd(once daily)/emtricitabine(FTC) (200mg qd) + efavirenz(EFV )(400mg qd; 2 x 200mg + 1 x placebo qd) all oral tablets

Placebo - identical taste and appearance without the active ingredients.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is to describe the CSF exposure of EFV when dosed at 400mg and 600mg daily.

CSF exposure will be assessed from CSF fluid and blood plasma from a special pharmacokinetic laboratory at Liverpook UK.</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The relationship between CSF EFV exposure and plasma exposure (CSF:plasma ratio)


CSF exposure will be assessed from CSF fluid and blood plasma from a special pharmacokinetic laboratory at Liverpook UK.</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The relationship between CSF EFV exposure and neuropsychiatric side effects (as assessed in main study protocol)


CSF exposure and neuropsychiatric side effects will be assessed from the main study data compared to CSF fuild and blood plasma exposure</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CSF HIV RNA measurement after 12 to 24 weeks of study therapy


CSF HIV RNA measurement will be assessed from CSF fluid and blood plasma using ultrasensitive RNA assay at imperial college, UK</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All subjects entering into the main study protocol at participating centres will be eligible to enter this sub-study</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Existing neurological disease which in the opinion of the
investigator would be a contra-indication to lumbar
puncture examination

CNS opportunistic infections in the past 12 weeks

Bacterial or viral meningitis in the past 12 weeks

Head injury requiring medical assessment in the past 12 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer on participants in the Main study.</concealment>
    <sequence>simple randomisation using a randomisation table created by computer software (ie computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>16/09/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Kirby Institute, University of New South Wales</primarysponsorname>
    <primarysponsoraddress>University of New South Wales
Anzac parade, Kensington
NSW 2052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Imperial college london</othercollaboratorname>
      <othercollaboratoraddress>Imperial College London
St. Mary's Campus
Winston Churchill Wing
Clinical Trials Centre
Praed Street
London W2 1NY</othercollaboratoraddress>
      <othercollaboratorcountry>United Kingdom</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Persistent HIV replication in the central nervous system (CNS) compartment may put subjects at risk of developing HIV-related brain disease. Important factors associated with the development of HIV-related brain disease include sub-therapeutic concentrations of antiretroviral drugs in the CNS.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NRES Committee North West - Greater Manchester West</ethicname>
      <ethicaddress>NRES Committee London - Fulham
HRA NRES Centre North West
Barlow House 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ</ethicaddress>
      <ethicapprovaldate>14/02/2011</ethicapprovaldate>
      <hrec>10/H0711/53</hrec>
      <ethicsubmitdate />
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Rebekah Puls</name>
      <address>University of New South Wales
Anzac parade, Kensington
NSW
2052</address>
      <phone>+61293850900</phone>
      <fax />
      <email>encore@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Carlo Dazo</name>
      <address>University of New South Wales
Anzac parade, Kensington
NSW
2052</address>
      <phone>+61293850900</phone>
      <fax />
      <email>encore@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Carlo Dazo</name>
      <address>University of New South Wales
Anzac parade, Kensington
NSW
2052</address>
      <phone>+61293850900</phone>
      <fax />
      <email>encore@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>